Description
CJC-1295 (no DAC) and Hexarelin is a research peptide blend combining GHRH receptor and ghrelin receptor agonists to model growth hormone signaling. CJC-1295 (Mod GRF 1–29) stimulates cAMP/PKA activity through GHRH receptor binding, while Hexarelin activates GHS-R1a to induce phospholipase C–mediated calcium release. This blend is used in studies of pituitary activation, peptide stability, and somatotropic regulation.
For research use only. Not for human consumption.
References:
Bowers CY et al., Endocrinology, 1990 126(2):1165–1171
Ghigo E et al., Eur J Endocrinol, 2001 145(1):1–10
Teichman SL et al., J Clin Endocrinol Metab, 2006 91(2):479–487




Reviews
There are no reviews yet.